TABLE 3.
Neoadjuvant Clinical Trials With Omission of Chemotherapy in HER2-Positive Breast Cancer
| Trial | Phase | Treatment Arms | Survival | n | pCR, % |
|---|---|---|---|---|---|
| PHERGain | II | TCHP | NR | 71 | 58 |
| HP ± ET | 3-year iDFS, 95% | 285 | 38 | ||
| WSG ADAPT HER2+/HR– | II | HP | 5-year OS, 94% | 92 | 34 |
| wTHP | 5-year OS, 98% | 42 | 90 | ||
| ADAPT-TP HER2+/HR+ | II | T-DM1 | 5-year OS, 97% | 119 | 41 |
| T-DM1 + ET | 5-year OS, 96% | 127 | 41 | ||
| H + ET | 5-year OS, 96% | 129 | 15 |
Abbreviations: C, carboplatin; ET, endocrine therapy; H, trastuzumab; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; NR, not reported; P, pertuzumab; pCR, pathological complete response; T, docetaxel; T-DM1, trastuzumab emtansine; wT, paclitaxel.